CY2366B1 - Process for the production of powdered pulmonary surfactant preparations. - Google Patents

Process for the production of powdered pulmonary surfactant preparations.

Info

Publication number
CY2366B1
CY2366B1 CY0300048A CY0300048A CY2366B1 CY 2366 B1 CY2366 B1 CY 2366B1 CY 0300048 A CY0300048 A CY 0300048A CY 0300048 A CY0300048 A CY 0300048A CY 2366 B1 CY2366 B1 CY 2366B1
Authority
CY
Cyprus
Prior art keywords
pulmonary surfactant
production
powdered
surfactant preparations
powdered pulmonary
Prior art date
Application number
CY0300048A
Other languages
English (en)
Inventor
Klaus Eistetter
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19602332A external-priority patent/DE19602332A1/de
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of CY2366B1 publication Critical patent/CY2366B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY0300048A 1996-01-24 2003-06-24 Process for the production of powdered pulmonary surfactant preparations. CY2366B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19602332A DE19602332A1 (de) 1996-01-24 1996-01-24 Verfahren zur Herstellung von pulverförmigen Lungensurfactant-Zubereitungen
EP96103442 1996-03-06

Publications (1)

Publication Number Publication Date
CY2366B1 true CY2366B1 (en) 2004-06-04

Family

ID=26022286

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0300048A CY2366B1 (en) 1996-01-24 2003-06-24 Process for the production of powdered pulmonary surfactant preparations.

Country Status (15)

Country Link
US (1) US6315983B1 (tr)
EP (1) EP0877602B1 (tr)
JP (1) JP3725166B2 (tr)
KR (1) KR100449789B1 (tr)
AT (1) ATE212220T1 (tr)
CA (1) CA2244767C (tr)
CY (1) CY2366B1 (tr)
CZ (1) CZ292186B6 (tr)
DE (1) DE59706180D1 (tr)
DK (1) DK0877602T3 (tr)
ES (1) ES2171883T3 (tr)
PT (1) PT877602E (tr)
TR (1) TR199801408T2 (tr)
UA (1) UA59358C2 (tr)
WO (1) WO1997026863A1 (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029098A1 (en) * 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
ATE365547T1 (de) * 1998-08-25 2007-07-15 Advanced Inhalation Res Inc Sprühgetrocknete proteinformulierungen
EP1767195A3 (en) * 1998-08-25 2007-04-04 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
DE69928279T2 (de) * 1998-11-10 2006-08-17 Altana Pharma Ag Lungensurfactant zubereitungen enthaltendes behandlungset
CA2372558A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
JP2003507411A (ja) * 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 噴霧乾燥大多孔性粒子製剤
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CA2384861A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2002338882B2 (en) 2001-10-11 2008-04-03 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel use of pulmonary surfactant
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US20030170223A1 (en) * 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
CN1642533A (zh) * 2002-03-18 2005-07-20 山之内制药株式会社 吸入用粉末医药组合物及其制备方法
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
WO2005115520A1 (en) * 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
AU2005268755B2 (en) * 2004-08-06 2011-04-07 Takeda Gmbh Composition comprising a pulmonary surfactant and a TNF-derived peptide
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
NZ588478A (en) 2008-03-17 2013-06-28 Discovery Lab Inc Ventilation circuit surrounding proximal aerosol delivery channel
ES2402241T3 (es) 2008-10-22 2013-04-30 Trudell Medical International Sistema de suministro de aerosol modular
AU2009324637B2 (en) 2008-12-10 2016-09-08 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2010111680A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2308489B1 (en) 2009-10-05 2014-01-01 Nutri-Fit GmbH & Co. KG Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock
WO2012025496A1 (en) 2010-08-23 2012-03-01 Nycomed Gmbh Humidified particles comprising a therapeutically active substance
PE20142302A1 (es) 2012-03-28 2015-01-21 Discovery Lab Inc Liofilizacion de tensoactivo sintetico liposomal pulmonar
EP3113816B8 (en) 2014-03-05 2020-04-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Device for providing a constant amount of aerosol and control system
BR112016020393B1 (pt) 2014-03-05 2022-03-29 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Umidificador para umidificar um aerossol
WO2015140125A2 (en) * 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
MX2018015969A (es) * 2016-06-24 2019-06-10 Civitas Therapeutics Inc Formulaciones tensoactivas para inhalacion.
JP7419253B2 (ja) * 2017-12-21 2024-01-22 キウィタス セラピューティクス，インコーポレイテッド 吸入のための界面活性剤製剤
MX2020006634A (es) 2017-12-21 2021-01-15 Civitas Therapeutics Inc Formulaciones de surfactantes para inhalacion.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58183621A (ja) * 1982-04-22 1983-10-26 Teijin Ltd 肺表面活性物質を有効成分とする粉末剤の調製法
DE3229179C2 (de) 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
JPS59164724A (ja) 1983-03-10 1984-09-17 Tokyo Tanabe Co Ltd サ−フアクタント及びそれを含有する呼吸窮迫症候群治療剤
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
DK0482097T3 (da) 1989-07-11 2001-09-17 Genentech Inc Tensidpræparater og fremgangsmåder
IN172208B (tr) * 1990-04-02 1993-05-01 Sint Sa
DK0553272T3 (da) 1990-10-17 2000-09-04 Liposome Co Inc Syntetisk lungesurfactant
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP3708553B2 (ja) * 1995-04-14 2005-10-19 ネクター セラピューティクス 向上した分散性を有する粉末型薬理組成物
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
ATE365547T1 (de) 1998-08-25 2007-07-15 Advanced Inhalation Res Inc Sprühgetrocknete proteinformulierungen

Also Published As

Publication number Publication date
CA2244767C (en) 2005-11-22
UA59358C2 (uk) 2003-09-15
DK0877602T3 (da) 2002-05-06
US6315983B1 (en) 2001-11-13
CA2244767A1 (en) 1997-07-31
DE59706180D1 (de) 2002-03-14
JP2000503976A (ja) 2000-04-04
JP3725166B2 (ja) 2005-12-07
EP0877602B1 (de) 2002-01-23
PT877602E (pt) 2002-07-31
CZ233898A3 (cs) 1999-02-17
WO1997026863A1 (de) 1997-07-31
KR100449789B1 (ko) 2005-02-03
EP0877602A1 (de) 1998-11-18
TR199801408T2 (tr) 1998-10-21
ES2171883T3 (es) 2002-09-16
KR19990081886A (ko) 1999-11-15
ATE212220T1 (de) 2002-02-15
CZ292186B6 (cs) 2003-08-13

Similar Documents

Publication Publication Date Title
CY2366B1 (en) Process for the production of powdered pulmonary surfactant preparations.
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
AU6073296A (en) Salt-stabilized enzyme preparations
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
SE8702907D0 (sv) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
ATE230612T1 (de) Stabile pulverförmige vitamin- und carotinoid- zubereitungen und vefahren zu deren herstellung
CA2108288A1 (en) Liposomal cyclosporin formulation and process for the preparation thereof
WO1998017319A3 (en) Platelet substitutes and conjugation methods suitable for their preparation
NO865079L (no) Fremgangsmaate for fremstilling av stabiliserte humanvevplasminogenaktivatorpreparater.
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
ES8704977A1 (es) Procedimiento de obtencion de un material en particulas a base de celulosa microcristalina
ES8403718A2 (es) Procedimiento de criodesecacion de sustancias cosmeticas y de diagnostico en solucion o suspension en disolventes.
JPS5782311A (en) Production of liposome preparation
AU2791689A (en) Medicinal preparation comprising the association of colistin,tobramycin and amphotericin b administered by atomization
AU6756287A (en) Nicorandil-containing preparation for injection
EP0402637A3 (en) Stable freeze dried polyhematoporphyrin ether/ester composition
HUP9900954A2 (hu) Eljárás por alakú tüdőfelület-aktív készítmények előállítására
HUT41235A (en) Pesticide, particularly insecticide compositions and process for preparing benzoyl-carbamides to be applied as active ingredients thereof
MY101266A (en) Pharmaceutical formulations
ES2007265A6 (es) Un metodo para preparar conjugados de indol-portador biologicamente activos.
JPS5290694A (en) Preparation of protoporphyrine 1x
JPS5696693A (en) Production of human standard enzyme sample from human placenta
MX9700484A (es) Leche sin lactosa y leche en polvo sin lactosa, y alimentos que los contienen y proceso para fabricarlos.
MX9702445A (es) Nuevos pirimido[1,2-]indoles.
DE3573724D1 (en) Use of 1,8,9-triacetoxy-anthracene as the active ingredient in the preparation of an antitumoral pharmaceutical compound